Insights Revealed in 2023 Turner Syndrome Pipeline Report: 4+ Companies and 4+ Promising Drugs in Focus - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Turner Syndrome - Pipeline Insight, 2023" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report presents comprehensive insights into the Turner Syndrome pipeline landscape, featuring 4+ companies and 4+ pipeline drugs. It provides detailed drug profiles, covering both clinical and nonclinical stage products, along with the therapeutics assessment based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the status of inactive pipeline products in this space.

Understanding Turner Syndrome:

Turner Syndrome, also known as congenital ovarian hypoplasia syndrome, is the most common sex chromosomal abnormality found in females. It occurs when one of the X chromosomes is missing, either partially or completely. In most cases, Turner Syndrome is not inherited and results from a random event during the formation of reproductive cells. However, certain cases may involve partial deletion of the X chromosome and can be passed from one generation to the next.

Key Emerging Drugs:

• LUM201 (Ibutamoren) by Lumos Pharma: LUM201 is a small molecule administered orally, promoting the secretion of Growth Hormone (GH) from the pituitary gland. It acts as an agonist of the GH Secretagogue Receptor, stimulating GH release. Lumos Pharma's LUM201 is currently in Phase I of drug development for Turner Syndrome, with plans for a Phase II trial.
• TransCon hGH by Ascendis Pharma: TransCon hGH is a sustained-release prodrug of human growth hormone (hGH) designed to provide a once-weekly treatment option for patients. Ascendis Pharma is developing TransCon hGH in Phase III as a potential therapy for Turner Syndrome.

Companies in Focus:

Apart from Lumos Pharma and Ascendis Pharma, the report covers other companies actively engaged in developing therapies for Turner Syndrome.

Market Drivers and Therapeutic Assessment:

The report identifies key market drivers and factors influencing Turner Syndrome research and development. It also offers a thorough therapeutic assessment of the emerging drugs, providing valuable insights to companies and academics seeking novel approaches to treat and improve Turner Syndrome.

Pipeline Development Activities:

The report provides insights into different therapeutic candidates in various stages of clinical development, ranging from Phase III to preclinical and discovery stages. It also analyzes the key players involved in developing these drugs.

Key Questions Answered:

The report addresses several key questions concerning Turner Syndrome research and development, including the number of companies developing drugs, the status of emerging drugs in mid-stage and late-stage development, and key collaborations and licensing activities related to Turner Syndrome therapeutics. It also explores recent trends, drug types, novel technologies, and clinical studies for Turner Syndrome.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/qlb5kc.

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.